Positive Mutation of EGFR Inhibitor Undergo Erlotinib, Gefitinib, Icotinib or Osimertinib Plus Chinese Medicine Versus EGFRTKIs Alone In Patients With NSCLC, A Regional Study East China

Management of non-small cell lung cancer has been changed dramatically since detection of EGFR mutation. The rate of EGFR mutation in East China is unknown. In China, lung cancer is the most frequently diagnosed cancer and the leading cause of cancer-related mortality. The five-year survival rate in patients with lung cancer varies from 3.7–32.9%, depending on stage and regional differences. The majority of the tumors were Stage IIIB or IV Advanced Lung Adenocarcinoma. The two year survival rate of the patients was 70.6%, the overall survival was 58.8%. Methods: We electronically searched CNKI, Pub Med, Cochrane from database inception and manually searched Chinese-language oncology journals to identify A Positive Mutation of EGFR Inhibitor Undergo Erlotinib, Gefitinib, Icotinib Or Osimertinib Plus Chinese Medicine Versus Erlotinib, Gefitinib, Icotinib Or Osimertinib Alone In Patients With NSCLC, A Regional Study East China. The quality of the included trials was assessed using the method of Cochrane. If heterogeneity existed among subgroups, then overall results (OS) were calculated based on a random-effects model; otherwise, a fixed effects model used. Results: Electronic database searches yielded 1450 citations with NSCLC. We identified full text articles retrieved for detailled evaluation 70. Sample size of each trial had calculated by Rev Man 5.3.